GLP-1 RA antiobesity medications: Talking about cost

Author(s):

Richard Payerchin

Key Takeaways

GLP-1 receptor agonists are effective for obesity treatment but are associated with high costs, impacting patient access.
Physicians should engage in transparent discussions with patients about the financial implications of GLP-1 RAs.
Dr. Robert Kushner highlights the importance of balancing treatment efficacy with affordability and accessibility for patients.
Experience in research and clinical practice informs strategies for addressing financial barriers in obesity treatment.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

The new GLP-1 RA drugs are effective – and expensive. How should physicians talk about this with patients? Robert Kushner, MD, discusses the financial factors that affect patient treatment for obesity. He has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!